Norway Asthma Therapeutics Market Size & Outlook
Norway asthma therapeutics market, 2018-2030 (US$M)
Related Markets
Norway asthma therapeutics market highlights
- The Norway asthma therapeutics market generated a revenue of USD 86.0 million in 2023 and is expected to reach USD 97.9 million by 2030.
- The Norway market is expected to grow at a CAGR of 1.9% from 2024 to 2030.
- In terms of segment, anti- inflammatories was the largest revenue generating drug class in 2023.
- Combination therapy is the most lucrative drug class segment registering the fastest growth during the forecast period.
Asthma therapeutics market data book summary
| Market revenue in 2023 | USD 86.0 million |
| Market revenue in 2030 | USD 97.9 million |
| Growth rate | 1.9% (CAGR from 2023 to 2030) |
| Largest segment | Anti- inflammatories |
| Fastest growing segment | Combination therapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Anti- inflammatories, Bronchodilators, Combination therapy |
| Key market players worldwide | Teva Pharmaceutical Industries Ltd, GSK PLC, Merck & Co Inc, Roche Holding AG, AstraZeneca PLC, Boehringer Ingelheim, Sanofi SA, Koninklijke Philips NV, BD, Corvus Pharmaceuticals Inc |
Other key industry trends
- In terms of revenue, Norway accounted for 0.3% of the global asthma therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK asthma therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,141.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Asthma Therapeutics Market Scope
Asthma Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway asthma therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to asthma therapeutics market will help companies and investors design strategic landscapes.
Anti- inflammatories was the largest segment with a revenue share of 64.3% in 2023. Horizon Databook has segmented the Norway asthma therapeutics market based on anti- inflammatories, bronchodilators, combination therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Similar to other European countries, Norway witnesses a high demand for asthma drugs due to the high prevalence of respiratory diseases in the country. Moreover, Norway is the respiratory chronic diseases hotspot in Europe due to higher infection rates of the disease, which makes it important for key players to formulate and maintain product availability.
Moreover, key players are focusing on developing newer formulations to meet the increasing demand for new-generation products in the market. Some of the leading asthma drugs players in the market are GSK plc, Viatris, and AstraZeneca, among others.
Reasons to subscribe to Norway asthma therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway asthma therapeutics market databook
-
Our clientele includes a mix of asthma therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway asthma therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Norway asthma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway asthma therapeutics market size, by drug class, 2018-2030 (US$M)
Norway Asthma Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
